Fadraciclib (CYC065), a novel CDK inhibitor, targets key pro-survival and oncogenic pathways in cancer

Cyclin-dependent kinases (CDKs) contribute to the cancer hallmarks of uncontrolled proliferation and increased survival. As a result, over the last two decades substantial efforts have been directed towards identification and development of pharmaceutical CDK inhibitors. Insights into the biological...

Descripción completa

Detalles Bibliográficos
Autores principales: Frame, Sheelagh, Saladino, Chiara, MacKay, Craig, Atrash, Butrus, Sheldrake, Peter, McDonald, Edward, Clarke, Paul A., Workman, Paul, Blake, David, Zheleva, Daniella
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Public Library of Science 2020
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7347136/
https://www.ncbi.nlm.nih.gov/pubmed/32645016
http://dx.doi.org/10.1371/journal.pone.0234103

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7347136/
https://www.ncbi.nlm.nih.gov/pubmed/32645016
http://dx.doi.org/10.1371/journal.pone.0234103

Ejemplares similares